Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Rapid Micro Biosystems Q1 2026 Earnings Call - Recurring Revenue Surges as Samsung Deal Drives Placements
Rapid Micro Biosystems delivered an 11% year-over-year revenue increase to $8 million in Q1 2026, fueled by a record 36% jump in product revenue and a 28% rise in recurring revenue, which now accounts...
- Total revenue grew 11% year-over-year to $8 million, driven by strong momentum in both system placements and recurring revenue streams.
- Product revenue surged 36% to $5.6 million, led by a record consumables quarter with over 30% growth as installed base utilization increased.
- Recurring revenue climbed 28% to $5.1 million, now representing 63% of total revenue and highlighting the shift toward a more predictable, service-heavy business model.
- +7 more takeaways
Inovio Pharmaceuticals Q1 2026 Earnings Call - FDA Review Proceeds Amidst Accelerated Approval Debate and Cash Runway Extended
Inovio Pharmaceuticals reported a streamlined first quarter with operating expenses down 13% as the company burns cash to advance its lead candidate, INO-3107, toward a PDUFA date of October 30, 2026....
- INO-3107 BLA review progresses with FDA completing mid-cycle review without raising new significant issues, setting stage for late-cycle review in Q3 2026.
- FDA has agreed to an informal meeting to discuss INO-3107's eligibility for accelerated approval, a critical regulatory hurdle for the October 30, 2026 PDUFA date.
- Inovio raised $16 million in an April 2026 public equity offering, strengthening its balance sheet and extending cash runway into Q1 2027.
- +7 more takeaways
Lightwave Logic Q1 2026 Earnings Call - Market Expansion and Silicon Photonics Integration
Lightwave Logic reported a 27% year-over-year revenue increase to approximately $29,000 for Q1 2026, while maintaining a strong cash position of $100 million after utilizing its existing shelf registr...
- Revenue for Q1 2026 reached approximately $29,000, marking a 27% year-over-year increase.
- Net loss for the quarter was $6.3 million, or $0.04 per share, compared to a net loss of $4.7 million in the prior year period.
- Cash on hand increased to approximately $100 million as of May 11, 2026, after utilizing existing shelf registrations.
- +12 more takeaways
Seer Q1 2026 Earnings Call - Revenue Misses Amid Academic Funding Slump, But Biobank Momentum and IP Defense Signal Long-Term Play
Seer reported a sharp Q1 2026 revenue decline to $2.8 million, driven by a prolonged slump in academic and government funding, lumpy service project timing, and increased competition from lower-priced...
- Q1 2026 total revenue fell 33% year-over-year to $2.8 million, missing expectations due to depressed academic funding, competitive pressure from inferior imitators, and a lumpy service pipeline that lacked a major Q1 project.
- Management reaffirmed full-year 2026 revenue guidance of $16 million to $18 million, projecting approximately 3% growth at the midpoint over 2025, citing a 9-to-12-month lag in consumable reorders from last year's strong instrument install base.
- Operating expenses were aggressively cut to $18.2 million, a $4.6 million year-over-year reduction, driven by lower employee compensation and professional services costs, demonstrating strict capital discipline despite the revenue headwinds.
- +7 more takeaways
Shoulder Innovations Q1 2026 Earnings Call - Revenue Surges 65% as New Product Launches and Commercial Execution Drive Upward Guidance
Shoulder Innovations delivered a blistering start to 2026 with first-quarter net revenue jumping 65% year-over-year to $16.7 million, fueled by aggressive commercial execution and successful new produ...
- Revenue accelerated to $16.7 million in Q1 2026, representing a 65% year-over-year increase and a 16% sequential jump, demonstrating strong momentum into the new fiscal year.
- Full-year 2026 revenue guidance was raised to $65–$68 million, reflecting 37–44% growth over 2025 and signaling management's high conviction in sustained commercial execution.
- Gross margins remained robust at 77.7%, up from 76.9% in the prior year, driven by improved average selling prices and the early benefits of cost-reduction initiatives.
- +7 more takeaways
ClearPoint Neuro Q1 2026 Earnings Call - 43% Revenue Growth Driven by IRRAS Acquisition and Record $12.1M Top Line
ClearPoint Neuro delivered a strong first quarter of 2026, reporting record revenue of $12.1 million, a 43% increase year-over-year. The growth was fueled by a 25% organic expansion in device sales an...
- Revenue surged 43% year-over-year to a record $12.1 million, driven by 25% organic device growth and the full contribution of the IRRAS acquisition.
- Gross margin expanded to 64%, up 4 percentage points from Q1 2025, primarily due to lower excess and obsolete inventory reserves.
- IRRAflow integration is proceeding smoothly, adding a dual-lumen catheter that extends brain access capabilities and addresses a portfolio gap.
- +7 more takeaways
Fluent Q1 2026 Earnings Call - Commerce Media Surges to 58% of Revenue as Company Transforms
Fluent is executing a decisive pivot from a legacy marketplace model to a high-growth Commerce Media platform. The company’s Commerce Media Solutions segment grew 104% year-over-year in Q1 2026, captu...
- Commerce Media Solutions revenue surged 104% year-over-year to $25.9 million, representing 58% of total consolidated revenue, up from just 23% a year prior.
- Total consolidated revenue fell 19% to $44.9 million, but this primarily reflects the divestiture of Call Solutions; continuing business revenue declined only 3% year-over-year.
- Gross profit in Commerce Media Solutions grew 78% year-over-year to $5.0 million, though management expects margins to return to the mid-20s as early-term incentives roll off throughout 2026.
- +7 more takeaways
GrabAGun Digital Holdings Q1 2026 Earnings Call - Margin Expansion and PEW Logistics Launch Signal a Structural Shift in Firearm Commerce
GrabAGun Digital Holdings delivered a quarter that defies the broader industry's stagnation. Revenue grew 11.1% to $25.9 million while adjusted NICS checks rose a mere 1.6%. Management attributes this...
- Revenue grew 11.1% year-over-year to $25.9 million, significantly outpacing the 1.6% rise in adjusted NICS background checks, signaling aggressive market share gains.
- Firearms product sales rose 10.5% to $21.7 million, driven by favorable product mix, AI-powered pricing, and expanded marketing capabilities.
- Gross margin expanded 107 basis points to 10.7% of net sales, reflecting a shift toward higher-margin firearms categories and improved pricing optimization.
- +7 more takeaways
Snail Inc Q1 2026 Earnings Call - Revenue Surges 35% as AAA Pipeline and Stablecoin Launch Gaining Traction
Snail Inc reported a sharp turnaround in Q1 2026, with net revenue jumping 35.7% to $27.3 million and net income flipping to a $2.1 million profit from a prior-year loss. The lift came from strong ARK...
- Net revenue rose 35.7% year-over-year to $27.3 million, driven by a $4.2 million increase in ARK: Survival Ascended sales, a $2.1 million rise in Bellwright revenue, and $2.5 million in deferred revenue recognized.
- Net income flipped to a $2.1 million profit from a $1.9 million loss in the prior year, with EBITDA surging 173.3% to $2.4 million from a $3.2 million loss.
- Total units sold jumped 42.6% to 2.2 million, with ARK franchise sales adding 500,000 units and Bellwright contributing 200,000 units, supported by the Steam Winter event and the Lost Colony DLC.
- +7 more takeaways
Talphera Q1 2026 Earnings Call - Niyad NEPHRO Study Exceeds 50% Enrollment Milestone, PMA Targeted for 2027
Talphera reported strong progress in its Phase 2 NEPHRO study for Niyad, a potential regional anticoagulant for CRRT, having surpassed the 50% enrollment milestone with over 90% of patients enrolled a...
- Talphera has exceeded the 50% enrollment milestone in its NEPHRO study for Niyad, with over 90% of patients enrolled across its 12 active sites.
- The company is on track to complete enrollment in the NEPHRO CRRT study in 2026 and file a PMA for potential FDA approval of Niyad in 2027.
- Talphera closed a $4.1 million financing tranche in Q1 2026, bringing its cash balance to $21.1 million as of March 31, 2026.
- +7 more takeaways